Replies to post #75687 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Right. As opposed to when Amgen licensed NEO. It was totally proven at that point. LOL

[DewDiligence]

Everyone knows ADXS is high-risk. The salient point you’re omitting is that NEO may be enough, all by itself, to warrant a much higher valuation.